Abstract
Vaccines are the best defense available against infectious diseases. Vaccine safety is of major focus for regulatory bodies, vaccine manufacturers, public health authorities, health care providers and the public as vaccines are often given to healthy children and adults as well as to pregnant woman. Safety assessment is critical at all stages of vaccine development. Effective, clear and consistent communication of the risks and benefits of vaccines and advocacy during all stages of clinical research (including the preparation, approvals, conduct of clinical trials through the post marketing phase) is critically important. This needs to be done for all major stakeholders (e.g. community members, Study Team, Health Care Providers, Ministry of Health, Regulators, Ethics Committee members, Public Health Authorities and Policy Makers). Improved stakeholder alignment would help to address some of the concerns that may affect the clinical research, licensing of vaccines and their wide-spread use in immunization programs around the world.
Keywords: Adverse events, clinical research, communicating, pharmacovigilance, safety, vaccine introduction.
Current Drug Safety
Title:Communicating Vaccine Safety During the Development and Introduction of Vaccines
Volume: 10 Issue: 1
Author(s): Sonali Kochhar
Affiliation:
Keywords: Adverse events, clinical research, communicating, pharmacovigilance, safety, vaccine introduction.
Abstract: Vaccines are the best defense available against infectious diseases. Vaccine safety is of major focus for regulatory bodies, vaccine manufacturers, public health authorities, health care providers and the public as vaccines are often given to healthy children and adults as well as to pregnant woman. Safety assessment is critical at all stages of vaccine development. Effective, clear and consistent communication of the risks and benefits of vaccines and advocacy during all stages of clinical research (including the preparation, approvals, conduct of clinical trials through the post marketing phase) is critically important. This needs to be done for all major stakeholders (e.g. community members, Study Team, Health Care Providers, Ministry of Health, Regulators, Ethics Committee members, Public Health Authorities and Policy Makers). Improved stakeholder alignment would help to address some of the concerns that may affect the clinical research, licensing of vaccines and their wide-spread use in immunization programs around the world.
Export Options
About this article
Cite this article as:
Kochhar Sonali, Communicating Vaccine Safety During the Development and Introduction of Vaccines, Current Drug Safety 2015; 10 (1) . https://dx.doi.org/10.2174/157488631001150407110435
DOI https://dx.doi.org/10.2174/157488631001150407110435 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Ligands: Fine Tuning the Transcriptional Activity of the Glucocorticoid Receptor
Current Pharmaceutical Design Molecular Aspects of Melatonin Treatment in Tinnitus: A Review
Current Drug Targets Advances in Studies on Neurodegenerative Diseases and their Treatments
Current Topics in Medicinal Chemistry Integrated System Pharmacology and <i>In Silico</i> Analysis Elucidating Neuropharmacological Actions of <i>Withania somnifera</i> in the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Agents for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Multimerization Improves Targeting of Peptide Radio-Pharmaceuticals
Current Pharmaceutical Design An Evidence-Based Review of Antitussive Herbs Containing Essential Oils in Traditional Persian Medicine
Current Drug Discovery Technologies Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews Monoamine Oxidase Inhibitors: Ten Years of Docking Studies
Current Topics in Medicinal Chemistry Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design Pharmacokinetic Evaluation of Callistemon viminalis Derived Natural Compounds as Targeted Inhibitors Against δ -Opioid Receptor and Farnesyl Transferase
Letters in Drug Design & Discovery In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The “Holy Grail” in Genetic Addiction Risk Testing
Current Psychopharmacology Determination of Propranolol and Naproxen in Urine by using Excitation-Emission Matrix Phosphorescence Coupled with Multivariate Calibration Algorithms
Current Pharmaceutical Analysis Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNA Landscape in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets pH-sensitive Self-associations of the N-terminal Domain of NBCe1-A Suggest a Compact Conformation under Acidic Intracellular Conditions
Protein & Peptide Letters η-Secretase: Reduction of Amyloid Precursor Protein η-Site Cleavage in Alzheimers Disease
Current Alzheimer Research The Drug Discovery Portal: A Computational Platform for Identifying Drug Leads from Academia
Current Pharmaceutical Design Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology